MEK Inhibitors May Overcome Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia
Activation of the MAPK/ERK pathway mediates resistance to PI3K inhibitors, researchers found.
All articles by Christina Bennett, MS
Acute Lymphoblastic Leukemia Patients With Half-Matched Donors See Improved Outcomes
Outcomes have improved during the past decade for patients with acute lymphoblastic leukemia who undergo haploidentical hematopoietic cell transplantation.
Upfront Low-Dose Chemo-Immunotherapy Safe, Effective for Elderly With CLL
A study was conducted to assess the safety and efficacy of fludarabine and cyclophosphamide combined with rituximab for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in elderly patients and those with comorbid conditions.
Sequencing-Directed Therapy Found to Benefit Patients With Advanced Cancers
The Michigan Oncology Sequencing Program involved patients with advanced solid tumors who underwent next-generation sequencing to identify variants and potentially guide treatment.
Adding Lenalidomide to R-CHOP Fails to Improve PFS in DLBCL Subtype
A team of investigators sought to assess the safety and efficacy of lenalidomide plus R-CHOP in patients with previously untreated activated B-cell-like subtype of diffuse large B-cell lymphoma.
Standard Radiotherapy Dose for Indolent Lymphoma Prevails in FoRT Trial
Investigators assessed outcomes following a radiotherapy dose of 4 Gy in 2 fractions vs 24 Gy in 12 fractions in patients with follicular lymphoma or marginal zone lymphoma.
10-Gene Sequencing Panel Could Identify Patients With MDS Likely to Relapse After Allogeneic HCT
Investigators tested the utility of ultra-deep genomic testing to predict relapse in patients with myelodysplastic syndrome initiating conditioning therapy for allogeneic hematopoietic cell transplant (alloHCT).
PARP Inhibition Associated With Increased Risk for Secondary MDS, AML
Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.
Study Finds Low Adherence to Lenalidomide Therapy in Multiple Myeloma
Lenalidomide is typically prescribed to individuals with multiple myeloma who have received at least 1 prior therapy.
BCMA-Directed CAR-T Therapy Shows Clinical Activity in Multiple Myeloma
A CAR-T therapy that targets B-cell maturation antigen showed clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma.
- Loading...
Loading...
Next post in ASH 2020
Loading... 
Loading...